Novo-Backed MapLight Seeks $251 Million in US IPO, Placement

MapLight Therapeutics Inc., a promising biotechnology company focused on neurological disorders, is aiming to raise $250.8 million through an initial public offering and private placement. This move is significant as it demonstrates the company's confidence in its potential, even amidst challenges like the US government shutdown that could complicate the listing process. Investors will be watching closely, as successful funding could accelerate the development of vital treatments for neurological conditions.